Biogen, a biotechnology company, has made changes to its board of directors ahead of its annual shareholder meeting. Three current directors will not stand for re-election and will be replaced by Susan Langer, who is currently serving as president of Souffle Therapeutics. The shake-up comes after board chair Stelios Papadopoulos announced he was stepping down from his post and will be succeeded by Caroline Dorsa. Langer is reportedly the partner of one of the outgoing directors, Alexander Denner, and the mother of his child. Biogen's new board will navigate the company through important developments including regulatory decisions on Alzheimer's antibody Leqembi and amyotrophic lateral sclerosis candidate Tofersen.
The changes in Biogen's board come amid an "important time" for the company with regulatory decisions expected soon on Alzheimer's antibody Leqembi and amyotrophic lateral sclerosis candidate Tofersen. The three outgoing directors are being replaced by Susan Langer, who is currently serving as president of Souffle Therapeutics. Board chair Stelios Papadopoulos is also stepping down from his position and will be succeeded by Caroline Dorsa. Langer reportedly has a personal relationship with one of the outgoing directors, Alexander Denner.